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Abstract 
Background: HIV-1 protease (PR) is essential for viral infectivity as it cleaves Gag and Gag-Pol polyprotein precursors 
during viral maturation. Recent evidence suggests that cellular proteins can also be cleaved by PR, perhaps represent-
ing an important viral strategy to counter host defense mechanisms. Receptor-interacting protein kinase 1 (RIPK1) and 
RIPK2 belong to a family of serine/threonine kinases with conserved domain architecture and important functions in 
apoptosis, necrosis and innate immunity.
Results: We found that RIPK1 and RIPK2 but not other members of the RIP kinase family are cleaved by HIV-1 PR. In 
RIPK1, we identified a putative PR cleavage site; a mutation at this site rendered RIPK1 resistant to PR cleavage. RIPK1 
and RIPK2 were cleaved during HIV-1 infection of T cell lines or primary activated CD4+ T cells. Interfering with the 
viral life cycle at different stages by the addition of specific inhibitors against RT, integrase, or PR, completely pre-
vented RIPK1 and RIPK2 cleavage. Cleavage of RIPK1 disrupted RIPK1/RIPK3 complex formation and RIPK1-mediated 
induction of NF-kB.
Conclusions: These findings indicate that RIPK1 and RIPK2 are targets of HIV-1 PR activity during infection, and their 
inactivation may contribute to modulation of cell death and host defense pathways by HIV-1.
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Background
HIV-1 has a compact genome that encodes only 15 pro-
teins [1]. For successful replication, HIV must rewire the 
host’s cellular machinery to exploit numerous key host 
factors. Many aspects of the viral life-cycle, including 
entry, integration and release of viral particles, rely on a 
complex network of interactions between viral and host 
proteins. Cells targeted by HIV-1 express a number of 
proteins that function to restrict HIV-1 infection, includ-
ing TRIM5α [2, 3], APOBEC3G [4–7] and Tetherin [8, 9]. 
Conversely, HIV-1 encodes a number of genes, such as 
Vif and Vpu, which counteracts these restriction factors.
The main function of the HIV-1 protease (PR) is to 
cleave the viral polypeptides Gag and Gag-Pol into 
mature proteins. Catalytic activity of PR is essential for 
the production of infectious progeny. PR has a complex 
specificity for substrate peptides with substrate shape 
rather than primary sequence being key for substrate 
recognition [10, 11]. PR is initially synthesized in an inac-
tive form as part of the Gag-Pol precursor. During virus 
assembly and budding, which takes place on the cyto-
plasmic side of the plasma membrane, high concentra-
tions of Gag and Gag-Pol lead to autoprocessing and the 
formation of a stable PR dimer with full catalytic activity 
[12–14].
Due to its degenerate substrate specificity, PR has also 
been found to cleave host cell proteins in  vitro or dur-
ing the course of infection (Additional file  1: Table S1). 
Cleavage of host factors by PR likely represents an impor-
tant viral countermeasure against cellular restriction. 
The ever-growing list of host cell substrates includes 
cytoskeletal proteins [15], caspase-8 [16] and eukaryotic 
translation initiation factor 4G [17]. The list was further 
expanded by recent systematic analyses of interactions 
between PR and host cell proteins [18, 19].
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RIPK1 and RIPK2 are members of the receptor inter-
acting protein kinase (RIPK) family [20–23]. RIPKs are 
serine/threonine kinases that regulate a variety of cellular 
processes such as cell death and innate immune responses 
to viral and bacterial infection [24, 25]. All seven family 
members share a signature kinase domain (KD) but have 
different protein–protein interaction motifs. RIPK1 con-
tains a C-terminal death domain (DD) that binds to death 
receptors such as tumor necrosis factor (TNF)-R1 and to 
DD-containing adaptor proteins. RIPK1 also contains an 
intermediate domain (ID) that features a RIP homotypic 
interaction motif (RHIM), which mediates interaction 
with RIPK3 [26] or other RHIM-containing proteins [27]. 
Activation of death receptors triggers the polyubiquitina-
tion of RIPK1 by inhibitors of apoptosis proteins (IAPs) 
[28, 29]. Ubiquitinated RIPK1 mediates activation of 
NF-κB and mitogen-activated protein kinases (MAPKs). 
In the absence of IAPs activity, de-ubiquitinated RIPK1 
forms a complex with caspase-8 and promotes induc-
tion of apoptosis [30, 31]. Under circumstances where 
caspase-8 function is compromised, RIPK1 can recruit 
RIPK3 and initiate an alternative form of cell death called 
programmed necrosis, or necroptosis [24, 32, 33].
Along with its signature KD, RIPK2 also contains a cas-
pase activation and recruitment domain (CARD). RIPK2 
is a crucial adaptor protein downstream of the cytosolic 
pattern recognition receptors NOD1 and NOD2, which 
sense evolutionarily conserved bacterial peptidogly-
can motifs [34, 35]. NOD2 also interacts with the mito-
chondrial outer membrane protein MAVS to stimulate 
interferon-inducing pathways involving IRF-family tran-
scription factors [36]. Like TNFR1 complexes, NOD1 
and NOD2 also interact with IAPs [37]. Activation of 
NOD1 and NOD2 leads to non-canonical ubiquitination 
and autophosphorylation of RIPK2, which in turn drives 
activation of NF-κB and MAPKs [38].
The RIPK family plays a key role in controlling viral 
infections; viral strategies that interfere with RIPK func-
tion have been described [39, 40]. Recently, an important 
role for RIPK1 in promoting activation of the NLRP3 
inflammasome during RNA virus infection was dem-
onstrated [41]. Furthermore, it was shown that RIPK1 
kinase activity is crucial for induction of necroptosis in 
response to vaccinia virus infection [42]. RIPK2 func-
tion has also been linked to protection against influenza 
A virus infection [43]. However, at present no association 
between the RIPK family and retroviral infection have 
been established.
Results
HIV‑1 PR binds RIP kinase family members
In their recent systematic analysis of HIV–human pro-
tein interactions, Jaeger et  al. [19] found that HIV-1 
PR bound to a number of human proteins including 
RIPK2. To independently confirm the reported RIPK2-
PR interaction, we over-expressed and affinity purified 
(AP) epitope tagged proteins in HEK293T cells. Since 
over-expression of wild-type PR is cytotoxic [44–46], a 
catalytically inactive PR mutant (D25 N) was used in our 
studies. We observed binding of PR (D25  N) to RIPK2. 
This interaction was specific for HIV-1 PR as RIPK2 did 
not bind other HIV proteins, including Vif, Vpr, Vpu, 
or Nef (Fig.  1a). We also found that over-expressed PR 
(D25N) bound to endogenous RIPK2 but not to β–actin 
(Fig. 1b). Again, this result was specific for HIV-1 PR as 
none of the other HIV proteins (n = 12) bound to endog-
enous RIPK2 (Additional file 2: Figure S1). We found that 
PR can also interact with RIPK1, but not RIPK3 (data not 
shown). Taken together, these results show that PR can 
selectively recognize members of the RIP kinase family.
RIPK1 and RIPK2 are cleaved by HIV‑1 PR
RIPK1, RIPK2 and RIPK3 are highly homologous to 
each other [47, 48] (Fig. 2a). We tested whether PR could 
cleave these three members of the RIPK family. Myc-
tagged RIPK1, RIPK2 or RIPK3 were over-expressed 
in HEK293T cells and co-transfected with increas-
ing amounts of a plasmid encoding PR. Although over-
expression of catalytically active PR is cytotoxic, cells can 
tolerate transfection with smaller amounts of PR plasmid 
DNA; cell death is only observed upon transfection of 
larger amounts of PR. Transfection of HIV-Gag, a known 
target of PR, served as positive control (Fig. 2b).
We observed cleavage of RIPK1 (Fig.  2c) and RIPK2 
(Fig. 2d) by PR under these experimental conditions. For 
both proteins, we observed the appearance of N-terminal 
cleavage products in the presence of minute amounts 
of PR plasmid DNA (0.5 ng/well). Complete cleavage of 
full length RIPK1 and RIPK2 was observed by co-trans-
fection of only 20  ng PR expression plasmid. Even at 
higher concentrations of PR, no cleavage of β–actin was 
observed. Notably, the highly homologous RIPK3 protein 
was not cleaved by PR (Fig. 2e). In addition, we did not 
observe any cleavage of the upstream receptors NOD1 
(Additional file  3: Figure S2A) and NOD2 (Additional 
file  3: Figure S2B), nor other crucial signaling proteins 
implicated in innate immune response to virus infec-
tion, including MAVS (Additional file 3: Figure S2C) and 
STING (Additional file 3: Figure S2D). Catalytic activity 
of PR was required for cleavage of RIPK1 and RIPK2 as 
no cleavage was observed upon transfection of catalyti-
cally inactive PR (D25N) (Additional file 3: Figure S2E). 
We also performed a detailed densitometric analysis of 
primary findings and bar graphs demonstrating compar-
ative levels of full-length proteins can be found as supple-
mental material (Additional file 4: Figure S10).
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We next asked whether cleavage of RIPK1 and RIPK2 
by PR could be prevented by the PR inhibitor Saquina-
vir (SQV), the first HIV-1 PR inhibitor approved by the 
Food and Drug Administration (FDA). Indeed, we found 
that addition of SQV can completely abolished PR cleav-
age of RIPK1 and RIPK2. Dose–response experiments for 
RIPK2 show that complete inhibition was achieved by 
addition of 1 μM SQV, with partial inhibition observed at 
0.1 μM (Additional file 3: Figure S2E).
As shown in Fig.  2f, HIV-1 PR can cleave RIPK1 and 
RIPK2 in  vitro. Incubation of total cell extracts with 
recombinant HIV-1 PR at a weight-to-weight ratio of 
1000 to 1 resulted in the cleavage of RIPK1 and RIPK2 
and the loss of full-length proteins. Cleavage of RIPK1 
and RIPK2 was completely prevented by addition of PR 
inhibitor SQV. Furthermore, PR did not cleave RIPK3 or 
β–actin in vitro.
It has previously been reported that PR cleaves and 
activates caspase-8 in vitro and during infection [16, 49, 
50]. As RIPK family members are known substrates of 
active caspase-8 [51–53], it is possible that the observed 
cleavage of RIPK1 and RIPK2 could actually be due to 
caspase-8 activation by PR. We found that caspase-8 was 
processed by PR although to a much lesser extend than 
RIPK1 or RIPK2 (Additional file 5: Figure S3). However, 
inhibition of caspase activity by the pan-caspase inhibitor 
zVAD-fmk did not affect RIPK1 or RIPK2 cleavage by PR. 
We confirmed that zVAD-fmk was active in protecting 
cells from caspase-8-induced apoptosis (data not shown). 
Nevertheless, PR processed RIPK1 and RIPK2 equally in 
the absence or presence of zVAD-fmk (Fig.  2g). There-
fore, RIPK1 and RIPK2 processing by HIV-1 PR is direct 
and does not dependent on the activation of caspases.
Taken together, our results demonstrate that PR cleaves 
RIPK1 and RIPK2 with high specificity.
Endogenous RIPK1 is cleaved by HIV‑1 PR
Having demonstrated that PR can cleave over-expressed 
RIPK1 and RIPK2, we next investigated if PR can cleave 
endogenously expressed proteins. Antibody selection 
proved critical for detecting endogenous RIPK cleavage 
products. A rabbit monoclonal antibody raised against 
the N-terminus of RIPK1 (Cell Signaling) detected full 
length RIPK1 and the N-terminal cleavage product of 
both over-expressed and endogenous RIPK1 (Fig.  3a; 
Additional file  6: Figure S4A). In contrast, a mouse 
monoclonal antibody raised against the C-terminal of 
RIPK1 (BD Transduction Lab) failed to detect any RIPK1 
cleavage products (Additional file  6: Figure S4A). Simi-
lar to our results for over-expressed proteins, cleavage 
of endogenous RIPK1 was absent in cells transfected 
with catalytically inactive PR or when treated with SQV 
(Fig. 3a). Furthermore, endogenous RIPK1 was processed 
in Jurkat cell lysates by recombinant PR in vitro (Fig. 3b).
Although we were able to detect cleavage of endog-
enous RIPK1, we have not yet been able to detect cleav-
age products of endogenous RIPK2 due to the lack of a 
suitable antibody. Furthermore, we have not been able 
to detect C-terminal cleavage products for either over-
expressed or endogenous RIPK1. We ruled out that sta-
bility of respective cleavage products could be affected 
by the absence or presence of an epitope tag. PR cleaved 
N- and C-terminally tagged versions of RIPK1 at similar 
efficiency (Additional file 6: Figure S4B).
To extend our findings to a second cell line, we gener-
ated Jurkat cell lines with doxycyline-(DOX) inducible 
expression of catalytically active or inactive PR. Since 
leakiness of DOX systems is a known issue, we validated 
the “tightness” of the system by introducing a firefly lucif-
erase reporter gene. Luciferase activity was undetectable 
(comparable to background levels) in non-induced cells 
(Additional file  7: Figure S5A). Furthermore, immuno-
blot analysis of cell lysates revealed undetectable lev-
els of PR expression in non-induced cells. Induction of 
Fig. 1 HIV PR binds RIP kinase family members. a HEK293T cells 
(1 × 106) were transiently transfected with indicated expression 
plasmids (1 μg each). Various Strep-FLAG- (SF-) tagged HIV-1 proteins 
were expressed along with Myc-tagged RIPK2. After 24 h, proteins 
were affinity purified from cleared cell lysates with Dynabeads 
Streptavidin. Affinity purifications (APs) or total lysates were subjected 
to SDS-PAGE and Western blot (WB) analysis. Proteins were revealed 
using the indicated antibodies. b HIV PR binds to endogenous 
RIPK2. Catalytically inactive (D25N) SF-tagged HIV PR was expressed 
in HEK293T cells. Mock-transfected cells (-PR) were used as con-
trol. Complexes were purified as above. APs or total lysates were 
subjected to SDS-PAGE and Western blot (WB) analysis. Proteins were 
revealed using antibodies against RIPK2 (BD Transduction Laborato-
ries) or β-actin (Sigma-Aldrich)
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PR expression with DOX resulted in the production of 
cleaved RIPK1 (Fig.  3c). Treating these cells with SQV 
prevented this cleavage. Time-course studies showed 
that cleaved RIPK1 appeared after 8  h of DOX incuba-
tion, with a maximum after 24 h (Additional file 7: Figure 
S5B). Addition of SQV prevented the cleavage of endog-
enous RIPK1 at all times assayed. Dose–response experi-
ments showed that elevated concentrations of DOX led 
to increased levels of cleaved RIPK1 in cells expressing 
catalytically active, but not inactive PR. (Additional 
file 7: Figure S5C). The second band observed in Figure 
S5B corresponds to a non-specific band and the differ-
ences compared to Fig. 3c can be attributed to batch-to-
batch variations of the rabbit RIPK1 antibody. To further 
demonstrate that the additional band is indeed due to 
unspecific binding of the primary antibody (and not an 
additional RIPK1 cleavage product) we repeated the 
experiment in RIPK1 deficient Jurkat cells. Although no 
Fig. 2 HIV-1 PR cleaves RIPK1 and RIPK2. a Domain architecture of RIPK family members. CARD caspase activation and recruitment domain, DD 
death domain, ID intermediate domain, KD kinase domain, RHIM RIP homotypic interaction motif. Illustration adopted from Festjens et al. [47]. b–e 
HEK293T cells were transfected with plasmids encoding Gag-SF (b), or Myc-tagged RIPK1 (c), RIPK2 (d), and RIPK3 (e) along with increasing amounts 
of plasmid encoding HIV-1 PR. After 24 h, cells were collected in lysis buffer and samples were subjected to SDS-PAGE and WB analysis. Proteins 
were revealed using antibodies against FLAG (for Gag), c-Myc (for RIPKs), β-actin, or HIV-1 PR. (F) HIV-1 PR cleaves RIPK1 and RIPK2 in vitro. HEK293T 
cells were transfected with expression plasmids encoding Myc-tagged RIPK1, RIPK2 or RIPK3. Cell lysates were prepared 24 h after transfection and 
incubated with recombinant HIV-1 PR (at a weight-to-weight ratio of 1000:1) in the absence or presence of SQV (5 μM). After 3 h of incubation at 
37 °C, lysates were subjected to SDS-PAGE and WB. Proteins were revealed using antibodies against c-Myc or β-actin (loading control). g HIV-1 PR 
cleaves RIPK1 and RIPK2 in the absence of caspase activity. HEK293T cells were transfected with expression plasmids encoding Myc-tagged RIPK1 or 
RIPK2 with (+) or without (−) catalytically active HIV-1 PR in the absence or presence of pan-caspase inhibitor zVAD-fmk. Cells were lysed 24 h after 
transfection and total cell extracts were subjected to SDS-PAGE and WB. Proteins were revealed using antibodies described above
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bands for full-length or cleaved RIPK1 were detected in 
lysates of RIPK1−/− Jurkat cells, the respective unspecific 
band was still visible (Additional file 7: Figure S5D).
We also tested whether PR mutations, which occur in 
patients with discordant responses to antiretroviral ther-
apy, differ in their ability to cleave RIPK1. We tested two 
discordance-associated mutations (DAMs), I54  V and 
V82A, which were previously shown to reduce the ability 
of PR to cleave caspase 8 [54]. Non-DAMs K20R, L63P, 
D30N and L90M served as negative controls. The active 
site dead D25G mutation served as positive control. 
With the exception of D25G (positive control), we did, 
however, not observe significant differences in RIPK1 
cleavage for any of the PR mutations tested (Additional 
file 8: Figure S6). This indicates that differential process-
ing of RIPK1 likely does not contribute to the discord-
ant responses observed in patients carrying the I54 V or 
V82A mutations in PR.
Taken together, our results provide multiple lines of 
evidence that PR can cleave endogenous RIPK1.
Identification of the PR cleavage site in RIPK1
We next used mass spectrometry to identify the precise 
cleavage site in RIPK1. To do so, we co-expressed Myc-
tagged RIPK1 and PR in HEK293T cells. The N-terminal 
fragment of cleaved RIPK1 was purified from total cell 
extracts by immunoprecipitation with an anti-Myc anti-
body and purified complexes were subjected to SDS-
PAGE analysis. A prominent band corresponding to the 
N-terminal cleavage product was submitted to mass 
spectrometry (Additional file  9: Figure S7A). Analysis 
revealed the presence of a non-tryptic peptide, corre-
sponding to amino acids 436–462 of human RIPK1. This 
indicates that the cleavage site is located in the ID region 
of RIPK1 (Fig. 4a).
To experimentally confirm the cleavage site, we made 
two mutants. A double mutation of positions 462–463 
from LY to NQ rendered RIPK1 resistant to PR cleavage 
(Fig.  4b). Introduction of a stop codon at position 463 
resulted in production of a truncated version of RIPK1 
(RIPK1 ΔC) that migrates at the exact same molecular 
size as the N-terminal RIPK1 cleavage product. Both of 
these findings suggest that the cleavage site is between 
L462 and Y463 (Fig. 4b).
Upon transfection of higher amounts of the PR expres-
sion construct (>10 ng per 1 × 105 cells), we observed the 
appearance of a RIPK1 cleavage product, which migrated 
at a higher molecular weight. This indicates the pres-
ence of a secondary PR recognition site in RIPK1, which 
can serve, though much less efficiently, as an alternative 
cleavage site once the primary cleavage site is unavailable 
(Additional file 9: Figure S7B).
RIPK1 and RIPK2 are cleaved during virus infection
Having established that ectopically expressed or puri-
fied HIV-1 PR can cleave RIPK1 and RIPK2 in various 
cell types, we next asked whether RIPK1 and RIPK2 are 
cleaved during HIV-1 infection. First, we over-expressed 
Myc-tagged versions of RIPK1, -2, and -3 in HEK293T 
cells and infected with different MOIs of VSV-G-pseu-
dotyped HIV-1 NL4.3. N-terminal cleavage products 
appeared 24  h after infection showing that RIPK1 and 
RIPK2 are cleaved during virus infection (Fig.  5a). As 
expected, addition of the PR inhibitor SQV completely 
blocked this cleavage. Moreover, treatment with AZT (an 
RT inhibitor) also inhibited RIPK1 and RIPK2 cleavage 
suggesting that integration and transcription of proviral 
genes are required for RIPK processing to occur. Impor-
tantly, RIPK3 was not cleaved under these conditions, 
demonstrating the specificity of our findings (Fig.  5b). 
We also quantified the levels of full-length and cleaved 
proteins and a comprehensive densitometric analysis of 
the band intensities in Fig. 5 can be found as supplemen-
tal material (Additional file 10: Figure S11).
Fig. 3 HIV-1 PR cleaves endogenous RIPK1. a HEK293T cells were 
transfected with empty vector (as control) or increasing amounts of 
an expression plasmid encoding catalytically active HIV-1 PR. Addition 
of SQV (5 μM) or transfection of catalytically inactive HIV PR D25 N 
served as negative controls. Cells were lysed 24 h after transfection 
and total cell extracts were subjected to SDS-PAGE and WB. Proteins 
were revealed using antibodies against RIKP1 (rabbit monoclonal 
antibody from Cell Signaling), β-actin, or HIV-1 PR. b HIV-1 PR cleaves 
endogenous RIPK1 in vitro. Jurkat cell lysates were incubated with 
recombinant HIV-1 PR (at a ratio of 1000:1) in the absence or presence 
of SQV (5 μM). After 3 h of incubation at 37 °C, lysates were subjected 
to SDS-PAGE and Western blotting (WB). Proteins were revealed using 
antibodies described above. c Jurkat cells with stably integrated Tet-
inducible vector encoding catalytically active HIV-1 PR were cultured 
without (-DOX) or with doxycycline (+DOX, 1 μg/ml) in the absence 
or presence of SQV (5 μM). Total cell lysates were prepared 24 h 
after treatment and subjected to SDS-PAGE and WB. Proteins were 
revealed using antibodies as described above
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Fig. 4 Identification of the PR cleavage site in RIPK1. a Primary sequence of human RIPK1 (aa 449–476 according to NCBI Reference Sequence 
NP_003795.2) with PR cleavage site between residues 462 and 463. Indicated point mutations were introduced by Quikchange mutatgenesis. b 
HEK293T cells were transfected with expression plasmids encoding wild-type (wt) RIPK1, RIPK1 with a double-mutation in the PR cleavage site 
(RIPK1 PRres), or RIPK1 with a non-sense mutation in the PR cleavage site (RIPK1 ΔC), respectively, along with catalytically active HIV PR (5 ng/well) in 
the absence (−) or presence (+) of SQV (5 μM). Cell lysates were subjected to SDS-PAGE and immunoblotting (WB). Proteins were revealed using 
antibodies against c-Myc, β-actin, or HIV-1 PR
Fig. 5 RIPK1 and RIPK2 are cleaved during HIV-1 infection. a, b HEK293T were transiently transfected with expression plasmids (0.5 μg/well) encod-
ing Myc-tagged RIPK1, RIPK2, or RIPK3, respectively. After 24 h, cells were infected with different MOIs of VSV-G pseudotyped HIV-1 NL4.3 in the 
absence or presence of SQV (5 μM) or AZT (10 μM). Cell lysates were prepared 8 or 24 h after infection and subjected to SDS-PAGE and immuno-
blotting (WB). Proteins were revealed using anti-Myc antibody. c, e Endogenous RIPK1 is cleaved during HIV-1 infection. c HEK293T were infected 
with different MOIs of VSV-G pseudotyped HIV-1 NL4.3. Cell lysates were prepared 24 h after infection and subjected to SDS-PAGE and immuno-
blotting (WB). Proteins were revealed using antibodies against RIPK1 (rabbit monoclonal antibody from Cell Signaling) or β-actin. d Sup-T1 cells 
or e primary activated CD4+ T cells were infected with increasing MOIs of replication-competent HIV-1 NL4.3. Cells were cultured with or without 
SQV (5 μM), Raltegravir (RAL), or Nevirapine (NVP), respectively. Cell lysates were prepared 48 h after infection and subjected to SDS-PAGE and WB. 
Proteins were revealed using antibodies against RIKP1 (rabbit monoclonal antibody from Cell Signaling), p24, or β-actin
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Next, we tested whether endogenous proteins are pro-
cessed during viral infection. Using non-transfected cells 
and a rabbit monoclonal antibody against RIPK1, we 
observed cleavage of endogenous RIPK1 in HEK293T 
cells infected with VSV-G-pseudotyped HIV-1 (Fig. 5c).
To validate our findings in a cell type with greater physi-
ological relevance, we infected Sup-T1 cells, a T cell line, 
with replication-competent HIV-1 NL4.3. Forty-eight 
hours after infection, we observed cleavage of RIPK1, 
which again could be inhibited with SQV suggesting that 
PR plays a key role in this event (Fig. 5d). The amount of 
cleaved RIPK1 correlated with the appearance of processed 
p24-Gag in the cell extracts. Importantly, interfering with 
the viral life cycle at different stages by the addition of spe-
cific inhibitors against reverse transcriptase (Nevirapine, 
NVP) or integrase (Raltegravir, RAL), completely prevented 
RIPK1 cleavage (Fig. 5d). We have also observed very simi-
lar results in CEM cells, another T cell line (Additional 
file 11: Figure S8). These data suggest that it is the PR syn-
thesized late in the viral life cycle and not the incoming PR 
that is responsible for processing of RIPK1.
We have also confirmed these findings in primary 
CD4+ T cells infected with replication-competent HIV-
1. Consistent with our previous findings, endogenous 
RIPK1 was cleaved in infected primary cells; this event 
was sensitive to treatment with inhibitors against PR or 
integrase (Fig. 5e).
Taken together, our results demonstrate cleavage of 
RIPK1 in T cell lines and primary CD4+ T cells during 
HIV-1 infection. This cleavage is observed at later time 
points of infection and is prevented not only by direct 
inhibition of PR, but also by addition of other inhibitors 
that interfere at early stages of the viral life cycle.
RIPK1 processing occurs in the absence of “incoming” PR
To further address the source of PR responsible for the 
observed cleavage of RIPK1—incoming viral particles or 
newly produced proteins in the infected cell—we trans-
fected HEK293T cells with proviral plasmids routinely 
used for production of lentiviral stocks, pNL4.3-Luc-
Env− (NIH AIDS Research Program, [55]) or psPAX2 
[56], in the absence of an Env-encoding plasmid. This 
ensures that released virions could not re-infect cells. 
Cleaved RIPK1 appeared 20 h after transfection of lenti-
viral plasmids (Additional file 12: Figure S9). The cleav-
age became more pronounced 40  h after tranfection 
and depended on the catalytic activity of PR. Addition 
of SQV at the time of transfection completely abolished 
RIPK1 processing. Cells transfected with psPAX2, which 
induces elevated expression of proviral genes from a 
CMV promoter, displayed more RIPK1 cleavage com-
pared to cells transfected with pNL4.3-Luc-Env−, which 
features LTR-driven expression of proviral genes.
Although we cannot exclude the possibility that PR 
delivered by virions at the time of infection can cleave 
RIPK1, our results indicate that the majority of RIPK1 
cleavage occurs due to post-integration expression of 
proviral genes. This explains why we did not detect 
cleaved RIPK1 at early time points or when the later 
stages of infection were blocked either with RT or inte-
grase inhibitors.
PR cleavage disrupts RIPK1 function
Having established that PR cleaves RIPK1 and RIPK2 
during HIV-1 infection, we sought to determine whether 
cleavage of RIPKs deregulated host processes that may 
impact virus replication. For example, RIPK1 is known to 
play a critical role in TNF signaling via NF-κB [57, 58]. 
However, when NF-κB signaling is impaired, cleavage of 
RIPK1 has been reported to play a key role in control-
ling apoptosis. RIPK1 can also initiate necroptosis by 
interacting with RIPK3 [30, 59]. We therefore conducted 
experiments to assess the effects of PR cleavage on these 
activities of RIPK1.
First, we examined if PR cleavage can diminish the 
ability of RIPK1 to activate NF-κB. Over-expression of 
RIPK1 in HEK293T cells leads to activation of NF-κB, 
as indicated by the induction of an NF-κB-driven lucif-
erase reporter gene. Co-expression of PR in this context 
resulted in a loss of luciferase activity that was completely 
restored by treatment with PR inhibitor SQV (Fig.  6a). 
Western blot analysis revealed that under these experi-
mental conditions levels of full-length RIPK1 were sig-
nificantly reduced and thus RIPK1 function was lost 
(Fig. 6b).
We also tested if PR cleavage can disrupt the interac-
tion of RIPK1 with RIPK3. For these experiments, we 
employed a mammalian 2-hybrid system to test whether 
PR could affect the interaction of RIPK1 with RIPK3. 
In this approach, binding of the two proteins drives the 
expression of a luciferase gene. As expected, RIPK1 and 
RIPK3 demonstrated a robust interaction (Fig.  6c). Co-
expression of increasing amounts of PR resulted in com-
plete loss of luciferase activity, indicating disruption of 
the RIPK1/RIPK3 interaction. Loss of luciferase activity 
was completely rescued by the addition of SQV (Fig. 6c). 
Importantly, the interaction of two unrelated proteins 
(p53 and large T antigen) was not affected by co-expres-
sion of PR (Fig.  6d). Taken together, these results dem-
onstrate that catalytic processing by PR disrupts critical 
RIPK1 functions.
Discussion
We have found that RIPK1 and RIPK2 are novel host sub-
strates of HIV-1 PR. Cleavage of RIPK1 and RIPK2 was 
observed in human cells expressing PR and when infected 
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with HIV-1. A small molecule inhibitor of PR completely 
blocked cleavage of RIPK1 and RIPK2. The PR cleavage 
site in RIPK1 was identified by mass-spectrometry and 
experimentally confirmed by showing that a mutation 
designed to disrupt the cleavage site inhibited processing. 
Over-expression of PR did not lead to promiscuous, non-
specific cleavage of host proteins, as shown for example 
by comparisons with RIPK3.
HIV-1 PR is known to target host proteins. This activ-
ity likely represents an important viral strategy to coun-
ter host restriction factors. However, the large numbers 
of putative host cell substrates found in recent proteom-
ics screens [18, 19] raises the question of how specific 
and how relevant PR-mediated cleavage of any given 
factor actually is. Over-expression of PR in vivo or high 
concentrations of PR in  vitro results in the proteolytic 
cleavage of many substrates. Studies under more physi-
ologically relevant conditions or actual viral infections 
result in selective cleavage of fewer targets. It is thus not 
surprising that the number of factors found cleaved dur-
ing viral infection will likely be far smaller than the total 
number of factors cleaved in  vitro (Additional file  1: 
Table S1). Although a number of potential host-encoded 
substrates have been reported for HIV-1, a limited subset 
of host proteins has been demonstrated to be cleaved in 
primary cell types targeted during the course of natural 
infection. Data presented here demonstrating cleavage of 
RIP kinases in CD4+ T cells challenged with HIV-1 indi-
cates that these proteins belong to this fraction of bona 
fide HIV-1 protease substrates.
In fact, RIPK1 and RIPK2 appear to be excellent sub-
strates for PR, based on the efficiency of their cleavage 
in cells expressing minute amounts of PR. The cleavage 
site we identified is consistent with predicted PR cleavage 
sites [60]. Defining a “consensus PR cleavage site” though 
is difficult, as PR is capable of cleaving a wide variety of 
amino acid sequences. The efficiency of by which PR 
cleaves multiple target sites in Gag and Gag-Pol varies 
considerably, and its different target sites display lim-
ited primary sequence homology. This is consistent with 
the hypothesis that substrate shape rather than primary 
sequence is important for substrate recognition by PR 
[61].
We have also sought to determine when in the viral life-
cycle does RIPK1 and RIPK2 get targeted for cleavage. It 
is important thus to know where and when PR becomes 
catalytically detectable within infected cells. It is well 
know that PR activity is critical for proteolytic process-
ing of viral precursor proteins thereby ensuing proper 
structural arrangements in newly released viruses. It is 
not entirely clear though how much catalytically active 
PR is present in HIV-1 infected cells. The mechanism by 
which PR is activated during viral assembly is not fully 
understood. PR is inactive within the Gag-Pro-Pol poly-
protein because the mature active enzyme is a dimer. Gag 
trafficking probably helps to regulate PR activation. Gag 
and Gag-Pol molecules arrive at the plasma membrane 
as oligomers, and polymerize into membrane-bound 
assembly sites where Gag levels increase exponentially 
[62, 63]. High concentrations of Gag and Gag-Pol precur-
sors facilitate formation of transient dimeric “encounter” 
complexes that have enzymatic activity. Within these, 
autoprocessing and formation of stable PR dimers with 
full catalytic activity can ensue [12]. PR activity in the 
cytosolic fraction of infected cells has also been docu-
mented [13, 14, 49]. This intracellular PR activity may 
allow for proteolytic processing of host cell proteins. PR 
activity might also play a role in early stages of infection. 
Fig. 6 Processing by HIV-1 PR disrupts RIPK1 function. a HEK293T 
cells harboring a stable NF-κB luciferase reporter were transfected 
by lipofection with an expression plasmid encoding RIPK1, or empty 
pcDNA. Cells were co-transfected with or without PR (20 ng/well), 
then cultured with or without SQV. After 24 h, cells were lysed by 
addition of Steady-GloR (Promega) and luciferase activity was meas-
ured using a standard plate luminometer. b Protein levels in a were 
analyzed using standard SDS-PAGE/Western blotting techniques. 
Proteins were revealed using antibodies against c-Myc, β-actin, or 
HIV-1 PR. Results are from a single experiment and are representative 
of at least three separate experiments. c, d Mammalian 2-hybrid sys-
tem. c HEK293T cells were transfected with plasmids encoding RIPK1 
fused to the GAL4 DNA-binding domain (RIPK1 only), RIPK3 fused to 
the GAL4 transcription activation domain (RIPK3 only), or a combina-
tion thereof (RIPK1/3). Cells were co-transfected with (+) or without 
(−) PR in the absence (n.t.) or presence (+) of SQV. d HEK293T cells 
were transfected with plasmids encoding p53 fused to the GAL4 
DNA-binding domain (p53 only), large T antigen fused to the GAL4 
transcription activation domain (T only), or a combination thereof 
(p53/T). Values represent mean ± standard deviation of triplicate 
cultures (mean ± SD, n = 3). Statistical significance was determined 
by unpaired t-tests, ****P ≤ 0.0001, ***P ≤ 0.001
Page 9 of 16Wagner et al. Retrovirology  (2015) 12:74 
It was reported that treatment with PR inhibitors reduces 
viral replication in a single cycle of infection presumably 
by altering the stability of unintegrated viral cDNA [64]. 
These data indicate that “incoming PR” can target host 
cell factors and counteract cellular restriction. While we 
cannot rule out that PR released during virus entry might 
target RIPK1 and RIPK2, our data suggest that RIPK1 
and RIPK2 cleavage occurs at later stages of infection and 
depends on transcription of viral genes. Thus, we favor 
the interpretation that “de novo” activity of PR is respon-
sible for RIPK1 and RIPK2 cleavage in HIV infected cells.
PR’s role in counteracting cellular immune mechanisms 
is just beginning to emerge. Our results show that PR 
cleavage disrupts the function of RIPK1. HIV-1 infec-
tion can elicit an innate immune response, resulting in 
the production of interferons (IFNs) or pro-inflammatory 
cytokines such as TNF-α. Known HIV-1 PAMPs include 
the viral capsid (CA) and viral nucleic acids such as the 
incoming RNA or the reverse-transcribed DNA [3, 65, 
66]. To successfully establish a persistent infection, HIV-1 
relies on a variety of countermeasures to suppress innate 
immune signaling.
Numerous HIV-mediated immune evasion strate-
gies have been described [67–69]. The ability of HIV to 
counteract host defenses has been linked to the pres-
ence of accessory genes, such as Vpu and Vif [9, 70, 71]. 
Our data suggest another mechanism by which HIV may 
counteract host innate immune responses—namely by 
cleaving and inactivating RIPK1 and presumably (though 
not tested here) RIPK2. HIV seems to possess redundant 
mechanisms for ensuring suppression of the type I IFN 
pathway. As demonstrated by Solis et  al., PR-mediated 
inhibition of RIG-I sensing contributes to viral suppres-
sion of the IFN response in macrophages [72]. Interest-
ingly, Rajput et  al. [53] demonstrated that cleavage of 
RIPK1 by caspase-8 inhibits type I IFN signaling down-
stream of the ribonucleic acid sensor RIG-I. In this con-
text, caspase-8-mediated cleavage of RIPK1 converts 
RIPK1 from a signaling enhancer to a signaling inhibitor. 
Based on these observations, we wondered whether PR 
could mimic the role of caspase-8 in attenuating type I 
IFN signaling by directly cleaving RIPK1 during HIV-1 
infection. Although preliminary experiments confirmed 
that over-expression of PR suppresses RIG-I-mediated 
type I IFN signaling, we were not able to find any evi-
dence that this suppression was linked to the ability of 
PR to cleave RIPK1. Moreover, subsequent experiments 
indicated that PR-mediated inhibition of RIG-I activity 
was not affected by the absence or presence of functional 
RIPK1 (data not shown).
However, RIPK1 integrates multiple signals from the 
innate immune system, including those generated in 
response to inflammatory cytokines and to detection 
of pathogens. Of particular interest is the recruitment 
of RIPK1 to various nucleic acid-sensing platforms. For 
example, RIPK1 was shown to promote IRF3 and NF-κB 
activation downstream of Toll-like receptors (TLRs) and 
the cytosolic DNA sensor DAI [27, 73]. RIPK1 interac-
tions with TLR3 or DAI are mediated by RHIM and play 
important roles during virus infection. PR cleavage there-
fore could impact numerous RIPK1 functions beyond 
the traditional role associated with its participation in 
TNFR1 signaling. Cellular responses controlled by RIPK1 
are diverse, and include the activation of MAP kinases 
and NF-κB as well as induction of both apoptotic and 
necrotic cell death [74].
RIPK1 interacts with RIPK3 through its RHIM domain. 
The RIPK1/RIPK3 interaction is critical for the induc-
tion of necroptosis, an inflammatory form of cell death, 
often observed upon DNA virus infection. Necroptosis 
leads to release of “danger signals” (endogenous PAMPs) 
that activate the immune response. Viruses try to limit 
necroptosis to avoid activation of the immune system. 
Some DNA viruses inhibit RIPK1-mediated induction of 
necroptosis by encoding RHIM-homology proteins [75]. 
Our data suggest that PR cleavage can disrupt RHIM-
mediated interaction of RIPK1 and RIPK3. Thus, another 
possibility is, during HIV infection, PR activity may mir-
ror the role of viral RHIM-homology proteins in sup-
pressing the induction of necroptosis.
Whereas the role of RIPK2 in defense to bacterial 
infection is well established, evidence for RIPK2 function 
in response to viral infection is just beginning to emerge. 
RIPK2 appears to play a protective role during influenza 
A virus infection. It does so, interestingly, in a kinase-
dependent manner by suppressing activation of the 
NLRP3 inflammasome via a mitochondrial pathway [43]. 
In response to certain DNA viruses, RIPK2 may also pro-
mote the induction of IFN downstream of pattern-recog-
nition receptor NOD2 [76]. The importance of RIPKs in 
combating viral infections is further highlighted by the 
fact that both RIPK1 and RIPK2 are known ISGs [77].
Interestingly, RIPK family members also have known 
connections to NLRs. RIPK1 function was shown do 
be essential for activation of the NLRP3 inflammasome 
upon infection with RNA viruses, such as Sendai virus 
or Influenza A [41]. Infection with RNA viruses triggers 
the formation of a RIPK1/RIPK3 complex, and inhibition 
of RIPK1 kinase function blocked viral-induced activa-
tion of the inflammasome. Since different reports sug-
gest that NLRs can be activated during HIV infection, 
the connection between RIPKs and NLRs is intriguing. 
HIV-1 can trigger NLRP3 inflammasome activation and 
release of IL-1β [78–81]. It has been suggested that gp120 
functions as the PAMP for inflammasome activation in 
HIV-infected cells since VSV-G pseudotyped viruses do 
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not elicit a response [81]. Whether HIV-1 infection leads 
to the formation of a RIPK1/RIPK3 complex that could 
promote NLRP3 inflammasome activation remains to be 
elucidated.
Ectopic expression of RIPK1 and PR results in levels of 
full-length RIPK1 that are significantly reduced (Fig. 2c). 
While we still observed cleavage of endogenous RIPK1 
after expression of PR or HIV-1 challenge, we were una-
ble to detect a corresponding reduction of full-length 
RIPK1 (Figs.  3a, 5). While the basis of this difference is 
currently unclear, we hypothesize that only a fraction of 
endogenous RIPK1 may be targeted by PR for cleavage, 
possibly dependent on unique subcellular localization, 
higher-order complex formation, or post-translational 
modifications. We further speculate that the kinetics of 
these event(s) may be altered with RIPK1 species that 
are newly synthesized after ectopic expression thereby 
making it more accessible for PR cleavage. Alternatively, 
cleavage of endogenous RIPK1 may trigger a feedback 
circuit that increases synthesis of RIPK1. These results 
suggest that the cleaved species of RIPK1 may possess 
dominant negative activity that impedes critical, yet 
unknown, cellular functions that facilitate HIV-1 replica-
tion and/or pathogenesis.
Proteolytic control of RIPK1-mediated functions has 
been extensively described in distinct contexts, and there 
are various examples where cleavage of RIPK1 impacts 
important biological processes despite modest changes in 
the levels of full-length protein. RIPK1 can be cleaved by 
cellular proteases such as caspase-8 [51] or by cathepsin 
B [82]. Activation of death receptors (TNF-R1, Fas, DR3, 
DR4 or DR5) promotes the caspase-mediated cleavage of 
RIPK1 resulting in the generation of biologically active 
fragments with distinct functions that modulate NF-κB-
mediated cell survival or death [51]. TNF signaling and 
concomitant inhibition of caspases by treatment with 
pan-caspase-inhibitor zVAD leads to increased phos-
phorylation and decreased cleavage of RIPK1, leading 
to TNF-induced necroptosis. Similarly, TLR stimulation 
or treatment with IFNs in the presence of zVAD results 
in RIPK1 phosphorylation and induction of necropto-
sis [83–85]. Moreover, RIPK1-mediated RIG-I-induced 
IRF3 activation appears to be controlled by recruitment 
of caspase-8 to the RIG-I-MAVS complex, as cells lack-
ing caspase-8 displayed dramatically elevated IRF3 acti-
vation in response to Sendai virus or transfected dsRNA 
[53]. A common phenomenon between our study and 
the reports described above is the extent to which RIPK1 
cleavage is observed. In all cases, levels of full-length 
RIPK1 remain relatively unchanged, but cleaved products 
persist within the cell and the proteolytic processing of 
RIPK1 is clearly of physiological relevance [51, 53, 82]. 
During HIV infection, the N-terminal RIPK1 cleavage 
product appears to be stable in the cell and it comprises 
the RIPK1 kinase domain (KD). However, elucidating the 
basis of the observed discrepancy between in  vitro and 
in vivo RIPK1 cleave by PR, as well as understanding the 
impact of this event on RIPK1 function, will be critical in 
determining the influence of this event on HIV-1 replica-
tion and pathogenesis.
Conclusions
Our results show that RIPK1 and RIPK2 are bona fide 
substrates of HIV-1 PR. Further investigation of the 
functional implications of this activity on potentially a 
diversity of innate and adaptive immune responses will 
provide critical insight towards strategies by which the 
virus manipulates host molecular circuits to promote 
pathogenesis. RIP kinase family members control a large 
number of cellular processes and are regulated through 
proteolytic cleavage. HIV-1 PR has likely evolved to 
mimic these cellular activities to establish a favorable 
environment for viral replication. The diverse roles of 
RIPK family members in response to other viruses are 
well documented. PR-mediated proteolytic modifica-
tion of RIPK1 and RIPK2 therefore likely represents an 
important strategy of HIV-1 to counter cellular restric-
tion and modulate the host response to infection.
Methods
Reagents
Doxycycline, Saquinavir, Azidodeoxythymidine (AZT), 
Nevirapine, and Raltegravir were purchased from 
Santa Cruz Biotechnology; human TNF-α was from 
Cell Signaling Technology; z-VAD-fmk was from R&D 
Systems; Birinapant was from BioVision; recombinant 
HIV-1 protease was from Prospec Tany TechnoGene; 
cOmplete Protease Inhibitor tablets were from Roche 
Diagnostics; all primers used for PCR and qRT-PCR 
were from IDT.
Cell lines and tissue culture
HEK 293T and Jurkat cells were purchased from ATCC. 
Sup-T1 and CEM-SS cells were obtained from the NIH 
AIDS Reagent Program. HEK 293T cells were cultured 
in Dulbecco’s Modified Eagle Medium (DMEM) supple-
mented with 10 % FBS (Thermo Scientific), l-glutamine 
and penicillin/streptomycin. Jurkat, Sup-T1, and CEM-
SS cells were cultured in Roswell Park Memorial Insti-
tute medium (RPMI-1640), supplemented with 10  % 
FBS, l-glutamine and penicillin/streptomycin. Stable 
Jurkat cell lines with Tet-inducible expression of HIV-1 
PR (Jurkat Tet-On-PR) or catalytically inactive HIV-1 
PR D25N (Jurkat Tet-On-PR D25 N) were generated fol-
lowing the manufacturer’s instructions (Lenti-X™ Tet-
OnR Advanced Inducible Expression System, Clontech 
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Laboratories). Stable transformants were selected using 
200 μg/ml G418 and 1 μg/ml puromycin.
Expression vectors
Coding regions of human RIPK1 (GenBankR accession 
number NM_003804), RIPK2 (NM_003821), and RIPK3 
(NM_006871) were PCR amplified and cloned into 
pcDNA3 carrying a N-terminal Myc-tag using standard 
molecular biology techniques. Identities of ORFs were 
sequence verified by 5′ and 3′ end sequencing. The plas-
mid encoding human RIPK1 was further used for crea-
tion of the RIPK1 PRres and RIPK1 ΔC mutants, using the 
QuikChange II Site-Directed Mutagenesis Kit (Agilent 
Technologies). To generate RIPK1 PRres, we employed 
the site-directed mutagenesis and oligonucleotides that 
altered Leu-Tyr at position 462 and 463 (according to 
NCBI Reference Sequence NP_003795.2) to Asn-Gln. 
The RIPK1 ΔC expression construct was similarly gener-
ated using site-directed mutagenesis and oligonucleotides 
that introduced a stop codon at position 463. For mam-
malian two-hybrid analysis, coding sequences of human 
RIPK1 and RIPK3 were subcloned into pCMV-BD and 
pCMV-AD (Stratagene). Plasmids encoding codon-opti-
mized versions of HIV-1 ORFs, including HIV-1 PR and 
PR (D25N), were kindly provided by Dr. Nevan Krogan 
[19]. Plasmids encoding discordance-associated muta-
tions of HIV-1 PR were kindly provided by Dr. Andrew 
Badley [54]. Plasmids encoding NOD1, NOD2, MAVS, 
and STING were property of our lab and were all in CMV 
promoter-driven vectors.
Affinity purifications and immunoblot analysis
For APs, 1 × 106 HEK 293T cells were seeded in 6-well 
plates and the next day transfected with 1–2 μg plasmid 
using LipofectamineR 2000 (Life Technologies). Twenty-
four hours after transfection, cells were detached and 
washed with ice-cold PBS. Cells were lysed in 1 ml ice-
cold lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 0.5 % 
Nonidet P40, supplemented with cOmplete Protease 
Inhibitor mix). Cell lysates were cleared by centrifugation 
at 14,000×g for 15  min. Cleared lysates were incubated 
with 5 μL Dynabeads M-280 Streptavidin for 2 h at 4 °C 
with rotation. The beads were washed 5× with ice-cold 
lysis buffer. Proteins were eluted by boiling in SDS-sam-
ple buffer at 95  °C for 5  min. APs or whole cell lysates 
were resolved on NovexR 4–20 % Tris–Glycine gels (Life 
Technologies), transferred to a nitrocellulose membrane 
using the Trans-BlotR Turbo™ system (BioRad), blocked 
with 5 % milk/TBST, probed overnight at 4  °C with pri-
mary antibodies, then incubated with fluorescent sec-
ondary antibodies for 1 h at room temperature. Proteins 
were detected and quantified using the Odyssey Infrared 
Imaging System (LI-COR Biosciences). The following 
primary antibodies were used: mouse monoclonal anti-
c-Myc (Santa Cruz Biotechnology), mouse monoclonal 
anti-FLAG M2 (Sigma), mouse monoclonal anti-HA 
(Santa Cruz Biotechnology), mouse monoclonal anti-β-
actin (Sigma), mouse monoclonal anti-RIP (BD Trans-
duction Laboratories), rabbit monoclonal RIP (D94C12) 
XPR antibody (Cell Signaling Technology), mouse mono-
clonal anti-RIP2/RICK (BD Transduction Laboratories), 
rabbit polyclonal anti-RIP3 (Abcam), mouse monoclo-
nal anti-p24 (MP Biomedicals), and mouse monoclonal 
anti-HIV-1 protease (Life Technologies). The secondary 
antibodies used were donkey (polyclonal) IRDyeR 680RD 
anti-Mouse IgG and donkey (polyclonal) DyeR 800CW 
anti-rabbit IgG (LI-COR Biosciences).
Protease cleavage studies
For protease cleavage studies, 5  ×  105 HEK 293T cells 
were seeded in 12-well plates and the next day cotrans-
fected with plasmids encoding HIV-1 Gag (as posi-
tive control) or indicated human proteins (0.5 μg/well), 
along with increasing amounts of plasmid encoding HIV 
protease (PR). Addition of SQV (5 μM) or transfection 
of plasmid encoding catalytically inactive HIV protease 
(D25 N) served as negative controls. Twenty-four hours 
after transfection, cells were detached and washed with 
ice-cold PBS. Cell pellets were lysed by addition of SDS-
sample buffer and incubation at 95 °C for 5 min. Total cell 
extracts (10 %) were subjected to SDS-PAGE and immu-
noblotting. For in vitro cleavage assays, HEK 293T or Jur-
kat cells were lysed in lysis buffer (50 mM Tris.Cl, pH 7.4, 
150 mM NaCl, 0.5 % NP-40, without protease inhibitors). 
Cell lysates were cleared by centrifugation at 14,000×g 
for 15 min. Protein concentration was determined using 
the Bio-Rad protein assay kit (Bio-Rad Laboratories). 
Cleared lysates were incubated with recombinant HIV-1 
protease (at a weight to weight ratio of 1000:1) at 37  °C 
for 3 h.
Sample preparation for mass spectrometry
Coomassie stained gel bands were cut to 1  ×  1  mm 
pieces and transferred to separate new ethanol rinsed 
eppendorff tube and were de-stained using 50 % ACN in 
50 mM Ammonium Bicarbonate. Following vacuum dry-
ing, proteins were reduced and alkylated by final concen-
tration of 5  mM DTT and 15  mM iodoacetamide prior 
to digestion by Trypsin at a final concentration of 25 ng/
μl in 50 mM ammonium bicarbonate for 1 h on ice and 
additionally 16 h more at 37  °C using shaking incubator 
to assure complete digestion. Digested Tryptic peptides 
were extracted from gels and transferred to a new tube 
by following elution process; 100 μl of water added to the 
gels, sonicated 10 min in water bath and then flowed by 
1 time in 5 % Formic acid in water and 4 time extraction 
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by 50  % Acetonitrile in 5  % Formic Acid in water, once 
in 70  % acetonitrile and last in 100  % acetonitrile; all 
extracted peptides were pooled together and were 
vacuum dried and re-dissolved in 20  μl of 0.1  % TFA. 
Digested peptides were then concentrated and desalted 
using a Millipore C18 Zip Tip (Millipore). The eluent 
were then vacuum dried and re-dissolved in 24 μl of LC/
MS loading buffer (2 % acetonitrile in 0.1 % formic acid 
in water).
Mass spectrometry
Eight microlitre of tryptic digested samples were loaded 
to the automated Nano LC- LTQ MS/MS (Thermo Scien-
tific, Waltham, MA, USA), using an Eksigent Nano 2D LC 
system, a switch valve, a C18 trap column (Agilent, Santa 
Clara, CA, USA), a Zorbax C18 peptide trap column 
(Agilent technologies), and a capillary reversed phased 
column (15 cm in length, 100 mm id) packed with 5 mm, 
Magic C18 AQ resin (Michrom) with an ADVANCE ESI 
source (Michrom) which is used to ionize the peptides 
as they elute from the RP column, using a linear gradient 
elution from buffer A (2 % acetonitrile in H2O plus 0.1 % 
formic acid) to 15  % buffer A plus 85  % buffer B (ACN 
plus 0.1 % formic acid) in 120 min. The LC/MS run was 
operated in the data dependent mode. Data on the four 
strongest ions above an intensity of 50 × 10e4 were col-
lected with dynamic exclusion enabled and the collision 
energy set at 35  %). The MS/MS spectra were analyzed 
by Sorcerer Enterprise v.3.5 release (Sage-N Research 
Inc.) with SEQUEST algorithm as the search program 
for peptide/protein identification. SEQUEST was set up 
to search the target-decoy ipi.Human.v3.73 database con-
taining protein sequences using trypsin for enzyme with 
the allowance of up to 2 missed cleavages, Semi Tryptic 
search and precursor mass tolerance of 1.5 amu. Differ-
ential search includes 16 Da for methonine oxidation and 
57 Da for cysteines to account for carboxyamidomethyla-
tion in case of alkylation of cysteines. The search results 
were viewed, sorted, filtered, and statically analyzed by 
using comprehensive proteomics data analysis software, 
Peptide/Protein prophet v.4.02 (ISB).
Isolation of human CD4+ T cells
Peripheral blood mononuclear cells (PBMC) were iso-
lated by Ficoll density gradient centrifugation (Histo-
paque; Sigma) from anonymous healthy human donors 
(Scripps Normal Blood Donor Services, The Scripps 
Research Institute). CD4+ T cells were negatively selected 
using magnetic beads (CD4+ T cell isolation kit II; Milte-
nyi Biotec) as per the manufacturer’s instructions. CD4+ 
T cells were cultured in RPMI 1640 supplemented with 
10  % FBS, l-glutamine, penicillin/streptomycin, and 20 
units/ml interleukin-2 (NIH AIDS Reagent Program). 
Lymphocytes were activated with 1 μg/ml phytohemag-
glutinin-P (PHA) (Sigma) for 48 h.
Preparation of virus stocks
The proviral plasmids pNL4.3 and pNL4.3-Luc-E− were 
obtained from the NIH AIDS Reagent Program. Replica-
tion-competent HIV was generated by transfecting HEK 
293T cells with the pNL4.3 proviral plasmid using Lipo-
fectamineR 2000. VSV-G pseudotyped NL4.3 for single-
cycle infections was generated by cotransfection of HEK 
293T cells with pNL43-Luc-E− and pHCMV-G. Two days 
after transfection, supernatants were collected, filtered 
(0.45  μm), concentrated using Lenti-X™ concentrator 
(Clontech Laboratories), aliquoted, and stored at −80 °C. 
Physical titers of the viral stocks were determined using 
the AlphaLISA HIV p24 Kit (Perkin Elmer LAS).
Virus infection
For detection of RIPK cleavage during single-round infec-
tion, HEK 293T were transiently transfected with RIPK1, 
RIPK2, or RIPK3 expression plasmids (0.5  μg/well). 
Twenty-four hours after transfection cells were infected 
with indicated MOIs of VSV-g pseudotyped HIV NL4.3 
in the presence or absence SQV (5 μM) or AZT (10 μM). 
Cell lysates were prepared 8 and 24 h post infection. For 
detection of RIPK cleavage during spreading-infection, 
Sup-T1 or CEM-SS cells were infected with increasing 
MOIs of replication-competent HIV NL4.3. Cells were 
spin-occulated at 1200×g for 60  min. Afterwards, cells 
were either left non-treated or treated with SQV (5 μM), 
Raltegravir (5  μM), or Nevirapine (5  μM). Cell lysates 
were prepared 48 h post infection. Primary CD4+ T cells 
were PHA activated for 48 h before infection with HIV 
NL4.3 by spin occulation. Cell lysates were prepared 48 h 
post infection.
Luciferase and cell viability measurement
For measurement of NF-kB activity, HEK 293T cells 
harboring a stable NF-κB luciferase reporter were trans-
fected with an expression plasmid encoding RIPK1, or 
empty pcDNA using Lipofectamine 2000 (Life Tech-
nologies). Cells were co-transfected with or without PR, 
then cultured with or without SQV. For mammalian 
two-hybrid assays, HEK 293T cells were transfected with 
pCMV-BD, pCMV-AD, and luciferase reporter plasmids 
(Stratagene). Twenty-four hours after transfection, fire-
fly luciferase activity was quantified with Britelite Plus 
(PerkinElmer). All experiments were performed in trip-
licate. Luciferase assays and cell viability assays were 
quantified by using the PHERAstar luminometer (BMG 
Labtech).
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Statistical analysis
Statistical analysis was performed using GraphPad Prism 
6 software.
Additional files
Additional file 1: Table S1. Host cell substrates of HIV-1 PR. Known 
host cell substrates of HIV-1 PR were curated from the scientific literature 
and listed according to their publication date. Supporting evidence for 
each substrate is specified along with respective references to original 
publications.
Additional file 2: Figure S1. Endogenous RIPK2 specifically binds HIV-1 
PR. Various SF-tagged HIV-proteins were expressed by transfection in 
HEK293T cells. After 24 hours, proteins were affinity purified from cleared 
cell lysates with Dynabeads Streptavidin. Affinity purifications (APs) or 
total lysates were subjected to SDS-PAGE and Western blotting (WB). 
Proteins were revealed using antibodies against RIPK2 (BD Transduction 
Laboratories), or FLAG (Sigma).
Additional file 3: Figure S2. HIV-1 PR does not cleave unrelated pro-
teins. (A)-(D) HEK293T cells were transfected with plasmids encoding Myc-
tagged NOD1 (A), and NOD2 (B), or FLAG-tagged MAVS (C), and STING 
(D) along with increasing amounts of plasmid encoding HIV-1 PR. After 
24 hours, cells were collected in lysis buffer and samples were subjected 
to SDS-PAGE and WB analysis. Proteins were revealed using antibodies 
against c-Myc, FLAG, β-actin, or HIV-1 PR. (E) Dose-dependent inhibition 
of RIPK2 cleavage. HEK293T cells were transfected with Myc-RIPK2 in the 
absence (-) or presence (+) of catalytically active HIV PR (PR) or catalyti-
cally inactive HIV PR (D25N) (10 ng/well) and increasing concentrations of 
PR inhibitor SQV. Cell lysates were subjected to SDS-PAGE and immunob-
lotting (WB). Proteins were revealed using using antibodies against c-Myc, 
β-actin, or HIV-1 PR.
Additional file 4: Figure S10. Quantification of signal intensities in 
Figure 2 and 3. Bands were visualized and quantified using an Odyssey 
Infrared Imaging System (LI-COR Biosciences). Results are from a single 
experiment and are representative of at least three separate experiments. 
All values were normalized to β-actin levels. (A) Bar graph demonstrating 
levels of full-length Gag-SF in Figure 2B (B) Bar graph demonstrating levels 
of full-length Myc-RIPK1 in Figure 2C. (C) Bar graph demonstrating levels 
of full-length Myc-RIPK2 in Figure 2D. (D) Bar graph demonstrating levels 
of full-length RIPK1 in Figure 3A.
Additional file 5: Figure S3. HIV-1 PR cleaves caspase-8. HEK293T 
cells were transfected with a caspase-8 expression plasmid along with 
increasing amounts of catalytically active HIV-1 PR. Addition of SQV (5 μM) 
or transfection of catalytically inactive HIV PR (D25N) served as negative 
controls. Cells were lysed 24 hrs after transfection and total cell extracts 
were subjected to SDS-PAGE and immunoblotting (WB). Proteins were 
revealed using antibodies against caspase-8 (rabbit polyclonal), β-actin, 
or HIV-1 PR.
Additional file 6: Figure S4. Detection of cleaved RIPK1 by different 
antibodies. HEK293T cells were transfected with expression constructs 
encoding (A) Myc-RIPK1 (N-terminally tagged) or (B) RIPK1-HA (C-termi-
nally tagged), respectively, along with increasing amounts of catalytically 
active HIV-1 PR. Addition of SQV (5 μM) or transfection of catalytically 
inactive HIV-1 PR D25N served as negative controls. Cells were lysed 24 
hrs after transfection and total cell extracts were subjected to SDS-PAGE 
and immunoblotting (WB). Proteins were revealed using the indicated 
antibodies.
Additional file 7: Figure S5. HIV-1 PR cleaves endogenous RIPK1 
in Jurkat cells. (A) Jurkat cells stable for doxycycline-(DOX)-inducible 
expression of firefly luciferase were treated with indicated concentrations 
of DOX, After 20 hours, cells were lysed by addition of one volume of 
Steady-GloR (Promega). Luciferase activity was measured using a standard 
plate luminometer (relative fluorescence units, RFU). Values represent 
means +/- standard deviation of triplicate cultures (means +/- SD, n= 
3). (B) Jurkat cells stable for DOX-inducible expression of HIV-1 PR were 
treated with DOX (1 μg/ml) in the absence or presence of PR inhibitor 
SQV (5 μM). At indicated time points, cells were collected in lysis buffer 
and total cell lysates were subjected to SDS-PAGE and immunoblotting 
(WB). Proteins were revealed using antibodies against RIPK1, β-actin, or 
HIV-1 PR. (C) Jurkat cells with DOX-inducible expression of catalytically 
active (wild-type) or catalytically inactive HIV-1 PR (D25N) were treated 
with increasing concentrations of DOX. After 20 hours, cells were col-
lected in lysis buffer and total cell lysates were analyzed by SDS-PAGE and 
immunoblotting (WB). Proteins were revealed using antibodies against 
RIPK1, β-actin, or HIV-1 PR. Arrowheads indicate cleaved RIPK1. Asterisks 
indicate non-specific bands. (D) Jurkat or Jurkat RIPK1-/- cells [58] stable 
for DOX-inducible expression of HIV-1 PR were treated with increasing 
concentrations of DOX. After 20 hours, cells were collected in lysis buffer 
and total cell lysates were analyzed by SDS-PAGE and immunoblotting 
(WB). Proteins were revealed using an antibody against RIPK1. Arrowheads 
indicate cleaved RIPK1. Asterisks indicate non-specific bands.
Additional file 8: Figure S6. Effect of discordance-associated mutations 
in PR on RIPK1 processing. HEK293T cells were co-transfected with an 
expression construct encoding My-tagged RIPK1 along with different PR 
mutants. Discordance-associated mutations, I54V and V82A, were tested 
along with unrelated mutations K20R, L63P, D30N and L90M. Transfection 
of wild-type PR, or the active site dead D25G mutation served as controls. 
Cells were either left non-treated or treated with Saquinvir (SQV, 5 μM). 
Cell lysates were prepared 24 hours after infection and subjected to SDS-
PAGE and immunoblotting (WB). Proteins were revealed using antibodies 
against c-Myc, β-actin, or HIV-1 PR.
Additional file 9: Figure S7. RIPK1 cleavage product submitted to mass 
spec analysis. (A) HEK293T cells were transfected with expression plasmids 
encoding Myc-tagged RIPK1 along with catalytically active HIV PR (50 ng/
well). Cells were lysed 24 hours after transfection and the N-terminal frag-
ment of cleaved RIPK1 was purified from total cell extracts by immunopre-
cipitation with an anti-Myc antibody. Purified complexes were subjected 
to SDS-PAGE analysis and proteins were visualized by Coomassie staining. 
(B) HEK293T cells were transfected with expression plasmids encoding 
wild-type (wt) RIPK1 or RIPK1 with a double-mutation in the PR cleavage 
site (RIPK1 NQ), respectively, along with along with increasing amounts 
of catalytically active HIV PR. Cell lysates were subjected to SDS-PAGE and 
immunoblotting (WB). Proteins were revealed using antibodies against 
c-Myc, β-actin, or HIV-1 PR.
Additional file 10: Figure S11. Quantification of signal intensities in 
Figure 5. Bands were visualized and quantified using an Odyssey Infrared 
Imaging System (LI-COR Biosciences). Results are from a single experiment 
and are representative of at least three separate experiments. All values 
were normalized to β-actin levels. (A) Bar graph demonstrating levels of 
full-length and cleaved Myc-RIPK1 in Figure 5A. (B) Bar graph demonstrat-
ing levels of full-length and cleaved Myc-RIPK2 based in Figure 5A. (C) 
Bar graph demonstrating levels of full-length and cleaved Myc-RIPK1 in 
Figure 5C. (D) Bar graph demonstrating levels of full-length and cleaved 
Myc-RIPK1 in Figure 5D. (E) Bar graph demonstrating levels of full-length 
and cleaved Myc-RIPK1 in Figure S8. (F) Bar graph demonstrating levels of 
full-length and cleaved Myc-RIPK1 in Figure 5E.
Additional file 11: Figure S8. RIPK1 is cleaved in T cell lines dur-
ing HIV-1 infection. CEM cells were infected with increasing MOIs of 
replication-competent HIV-1 NL4.3. Cells were either left non-treated 
or treated with Saquinvir (SQV, 5 μM), Raltegravir (RAL), or Nevirapine 
(NVP), respectively. Cell lysates were prepared 48 hours after infection and 
subjected to SDS-PAGE and immunoblotting (WB). Proteins were revealed 
using antibodies against RIKP1 (rabbit monoclonal antibody from Cell 
Signaling), p24, or β-actin.
Additional file 12: Figure S9. RIPK1 processing occurs in the absence 
of “incoming” PR. HEK293T cells were transiently transfected with proviral 
plasmids pNL4.3-Luc-Env- (NIH AIDS Research Program) and psPAX2, 
respectively. Cells were either left non-treated or treated with Saquinvir 
(SQV, 5 μM). Transfection with pcDNA served as negative control. Cell 
lysates were prepared 20 or 40 hours after transfection and subjected 
to SDS-PAGE and Western blotting (WB). Proteins were revealed using 
antibodies against RIKP1 (rabbit antibody), or p24.
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